Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.
immunotherapy
microsatellite instability
pancreatic cancer
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
22
01
2020
revised:
08
04
2020
accepted:
10
04
2020
pubmed:
1
5
2020
medline:
31
7
2021
entrez:
1
5
2020
Statut:
ppublish
Résumé
Recently, tumours with microsatellite instability (MSI)/defective DNA mismatch repair (dMMR) have gained considerable interest due to the success of immunotherapy in this molecular setting. Here, we aim to clarify clinical-pathological and/or molecular features of this tumour subgroup through a systematic review coupled with a comparative analysis with existing databases, also providing indications for a correct approach to the clinical identification of MSI/dMMR pancreatic ductal adenocarcinoma (PDAC). PubMed, SCOPUS and Embase were searched for studies reporting data on MSI/dMMR in PDAC up to 30 November 2019. Histological and molecular data of MSI/dMMR PDAC were compared with non-MSI/dMMR PDAC and with PDAC reference cohorts (including SEER database and The Cancer Genome Atlas Research Network - TCGA project). Overall, 34 studies with 8323 patients with PDAC were included in the systematic review. MSI/dMMR demonstrated a very low prevalence in PDAC (around 1%-2%). Compared with conventional PDAC, MSI/dMMR PDAC resulted strongly associated with medullary and mucinous/colloid histology (p<0.01) and with a PDAC showing typical medullary or mucinous/colloid histology should be routinely examined for MSI/dMMR status using specific tests (immunohistochemistry, followed by MSI-PCR in cases with doubtful results). Next-generation sequencing (NGS) should be adopted either where there is limited tissue or as part of NGS tumour profiling in the context of precision oncology, acknowledging that conventional histology of PDAC may rarely harbour MSI/dMMR.
Identifiants
pubmed: 32350089
pii: gutjnl-2020-320726
doi: 10.1136/gutjnl-2020-320726
pmc: PMC7211065
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
148-156Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: LDW has been a paid consultant for PGDx (Personal Genome Diagnostics, Baltimore, MD, USA). CL has been a paid expert-consultant on microsatellite instability for BioScience Communications (New York, New York, USA).
Références
Am J Surg Pathol. 2012 Nov;36(11):1592-608
pubmed: 23026934
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii36-viii40
pubmed: 31605106
Surg Oncol. 2019 Mar;28:121-127
pubmed: 30851885
PLoS One. 2018 Dec 7;13(12):e0208557
pubmed: 30532127
Pol J Pathol. 2003;54(1):31-7
pubmed: 12817878
PLoS One. 2017 Nov 9;12(11):e0176181
pubmed: 29121062
JAMA Oncol. 2017 Jun 1;3(6):774-783
pubmed: 27768182
Cancer Res. 1993 Nov 1;53(21):5087-9
pubmed: 8221640
Gastroenterology. 2018 Mar;154(4):1061-1065
pubmed: 29158190
Cancer Res. 2001 Apr 1;61(7):3139-44
pubmed: 11306499
Ann Oncol. 2019 Aug 1;30(8):1232-1243
pubmed: 31056702
Pancreatology. 2005;5(2-3):220-7; discussion 227-8
pubmed: 15855819
Cancer Res. 1998 Nov 15;58(22):5248-57
pubmed: 9823339
Oncol Rep. 2000 Nov-Dec;7(6):1371-5
pubmed: 11032947
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Pancreatology. 2015 Jul-Aug;15(4):387-391
pubmed: 25959245
Ann Oncol. 2019 Jul 1;30(7):1096-1103
pubmed: 31038663
Mod Pathol. 2019 Dec;32(12):1806-1813
pubmed: 31285527
Br J Cancer. 1999 Apr;80(1-2):11-6
pubmed: 10389971
Cell Oncol (Dordr). 2012 Apr;35(2):119-26
pubmed: 22351431
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Cancer Res. 1995 Oct 1;55(19):4264-7
pubmed: 7671233
Genes Chromosomes Cancer. 1998 Jun;22(2):138-44
pubmed: 9598801
Cancer Genet Cytogenet. 2009 Feb;189(1):5-14
pubmed: 19167606
Clin Cancer Res. 1998 Apr;4(4):1071-4
pubmed: 9563904
PLoS One. 2012;7(9):e46002
pubmed: 23029359
Cancer Res. 1994 May 15;54(10):2761-4
pubmed: 8168108
Int J Cancer. 2017 Apr 1;140(7):1551-1563
pubmed: 27997699
Cancer Res. 2000 Apr 1;60(7):1835-9
pubmed: 10766168
Gut. 2000 Jun;46(6):842-8
pubmed: 10807898
J Pathol. 2014 Jul;233(3):217-27
pubmed: 24604757
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Eur J Surg Oncol. 1996 Oct;22(5):474-7
pubmed: 8903488
Clin Cancer Res. 2018 Sep 15;24(18):4444-4454
pubmed: 29661773
Int J Oncol. 2002 Nov;21(5):949-56
pubmed: 12370740
Int J Epidemiol. 2018 Apr 1;47(2):427-439
pubmed: 29149259
J Clin Oncol. 2019 Feb 1;37(4):286-295
pubmed: 30376427
Lancet Gastroenterol Hepatol. 2019 Oct;4(10):805-810
pubmed: 31511204
Clin Cancer Res. 2018 Mar 15;24(6):1326-1336
pubmed: 29367431
Am J Pathol. 2000 May;156(5):1641-51
pubmed: 10793075
Gastroenterology. 2017 Jan;152(1):68-74.e2
pubmed: 27856273
Virchows Arch. 2004 Jun;444(6):527-35
pubmed: 15057558
Am J Pathol. 1998 Jun;152(6):1501-7
pubmed: 9626054
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Jpn J Clin Oncol. 2019 Feb 1;49(2):174-182
pubmed: 30541038
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Mod Pathol. 2015 Oct;28(10):1383-9
pubmed: 26226846
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Clin Cancer Res. 2002 Aug;8(8):2536-40
pubmed: 12171881
Mod Pathol. 2003 Jun;16(6):537-42
pubmed: 12808058
Oncotarget. 2015 Mar 30;6(9):7209-20
pubmed: 25797243
Gastroenterology. 2019 Jun;156(8):2242-2253.e4
pubmed: 30836094
Gastroenterology. 2015 Mar;148(3):556-64
pubmed: 25479140
Oncol Rep. 2003 Jul-Aug;10(4):997-1000
pubmed: 12792759
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Mol Cancer Res. 2018 May;16(5):805-812
pubmed: 29523759